Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Natco Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹826.50
High
₹841.80
Price Summary
| Previous Close | ₹828.65 |
|---|---|
| Day's Range | ₹826.50 - ₹841.80 |
| Open | ₹839.00 |
| 52 Week Range | ₹789.00 - ₹1,226.80 |
| Volume | 4,45,370 |
| Market Cap | ₹0.01 |
| Previous Close | ₹829.00 |
|---|---|
| Day's Range | ₹827.55 - ₹846.95 |
| Open | ₹846.95 |
| 52 Week Range | ₹789.30 - ₹1,226.10 |
| Volume | 25,588 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 3,704.54 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.60 |
| Price/Earning (TTM) | 12.98 |
| TTM EPS (₹) | 63.89 |
| P/E Ratio | 12.30 |
| Book Value(₹) | 1.59 |
| PAT Margin (%) | 29.20 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 17.16 |
| Trade Value ( ₹ in Lacs) | 213.16 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.60 |
| Price/Earning (TTM) | 12.98 |
| TTM EPS (₹) | 63.89 |
| P/E Ratio | 12.30 |
| Book Value(₹) | 1.59 |
| PAT Margin (%) | 29.20 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 17.16 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 13289.0 | 40945.0 |
| Expenses | N/A | N/A |
| PBT | 5719.0 | 22260.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 4803.0 | 18504.0 |
About Natco Pharma Ltd.
| Founded | 1981 |
|---|---|
| Managing Director | V C Nannapaneni |
| NSE Symbol | NATCOPHARM |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,55,633.71 | 1,899.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,41,576.41 | 9,100.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,84,478.41 | 4,850.00 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,24,661.30 | 8,670.00 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,18,977.24 | 684.05 | 0.00 - 0.00 |
| Cipla Ltd. | 1,11,888.39 | 1,385.00 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,11,820.18 | 1,121.00 | 835.50 - 835.50 |
| Laurus Labs Ltd. | 99,417.45 | 1,840.00 | 823.10 - 823.10 |
| Lupin Ltd. | 96,528.82 | 2,111.00 | 1,900.00 - 1,900.00 |
| Dr. Reddy's Laboratories Ltd. | 96,322.06 | 1,154.00 | 1,101.00 - 1,101.00 |
No Records Found
Latest News
NATCO Pharma submits investor presentation
Natco Pharma informs about press release
NATCO Pharma informs about disclosure
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, NATCO Pharma has informed that it enclosed the disclosure as per format provided in SEBI Master Circular dated 30th January 2026.
Emmessar Biotech & Nutrition informs about newspaper add
SMS Pharmaceuticals informs about newspaper advertisement
Pursuant to Regulations 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has informed that it enclosed copies of the newspaper advertisement published on 5th September, 2026, intimating the dispatch of Notice of 38th Annual General Meeting and Integrated Annual Report for the financial year 2025-2026 for convening the 38th Annual General Meeting to be held on Tuesday, 29th September, 2026 at 10.30 AM (IST) through Video Conferencing or Other Audio Visual Means, without physical presence of the members at a common venue, in compliance with the Circular Nos. 14/2020, 17/2020, 20/2020, 02/2021, 21/2021, 2/2022, 10/2022, 09/2023, 09/2024 and 03/2025 dated 08th April, 2020, 13th April, 2020, 05th May, 2020, 13th January, 2021, 14th December, 2021, 05th May, 2022, 28th December, 2022, 25th September 2023, 19th September, 2024 and 22nd September, 2025 (collectively referred to as ‘MCA Circulars’) and Securities and Exchange Board of India. The advertisement has published in the newspapers: Financial Express (in English language) and Nava Telangana (in Telugu language). The newspaper advertisements are also made available on the website of the Company www.smspharma.com at Investors section.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Natco Pharma Ltd. is ₹828.65 as of 2026-09-04.
The market capitalisation of Natco Pharma Ltd. is ₹14,848.21 as of 2026-09-04.
The 1-year return of Natco Pharma Ltd. is -24.10% as of 2026-09-04.
The P/E ratio of Natco Pharma Ltd. is 12.30 as of 2026-09-06.
The 52-week high and low of Natco Pharma Ltd. are ₹1,226.80 and ₹789.00, respectively, as of 2026-09-04.
People Also Ask
Natco develops generic and specialty drugs, with strong positions in oncology, cardiology, gastro, and CNS, plus agro‑chemicals through its crop‑health division.
Natco collaborates on licensing, contract manufacturing, and supplies hospital‑focused oncology generics and complex formulations in India and export markets.
Natco Pharma is an Indian pharmaceutical company that researches, develops, manufactures, and markets generic medicines, oncology‑focused products, active pharmaceutical ingredients (APIs), and agro‑health solutions for domestic and international markets.
NATCO is the brand and corporate name used by Natco Pharma Limited. The company does not prominently use or disclose an official expanded form of the abbreviation in its public corporate identity.
Before it became Natco Pharma Limited, the company was initially known as Natco Fine Pharmaceuticals, under which it started its operations in thepharmaceutical sector.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
